In a CYP2C19 poor metabolizer who has had a recent minor (National Institutes of Health Stroke Scale ≤3) non‑cardioembolic ischemic stroke, what antiplatelet regimen is recommended?

Recommended Antiplatelet Regimen for CYP2C19 Poor Metabolizers with Recent Minor Stroke

For CYP2C19 poor metabolizers with recent minor non-cardioembolic ischemic stroke (NIHSS ≤3), dual antiplatelet therapy with ticagrelor 90 mg twice daily plus aspirin should be initiated within 24 hours and continued for 21-30 days, followed by single antiplatelet therapy. This recommendation is based on the most recent high-quality evidence demonstrating superior efficacy in this specific genetic population.

Rationale and Evidence

The 2023 World Stroke Organization guidelines 111 establish that for minor ischemic stroke (NIHSS ≤3), dual antiplatelet therapy (DAPT) should be initiated early. However, the critical issue for CYP2C19 poor metabolizers is that clopidogrel is essentially ineffective because they cannot convert the prodrug to its active metabolite 2.

Why Ticagrelor Over Clopidogrel

The CHANCE-2 trial 3 provides the highest-quality, most recent evidence specifically addressing your question. This randomized, double-blind trial of 6,412 Chinese patients with minor stroke or TIA who were CYP2C19 loss-of-function carriers demonstrated:

• Ticagrelor-aspirin reduced 1-year stroke recurrence to 7.91% versus 9.73% with clopidogrel-aspirin (HR 0.80,95% CI 0.68-0.95, p=0.007)
• No increase in severe or moderate bleeding (0.53% vs 0.63%, p=0.61)
• The benefit was established within the first 90 days and maintained at 1 year

A 2026 retrospective cohort study 4 corroborated these findings in real-world practice, showing that among poor metabolizers, ticagrelor reduced major adverse cardiovascular events from 30% to 10% (p=0.025) compared to clopidogrel, with no increase in bleeding risk.

Specific Treatment Algorithm

Acute Phase (First 24 Hours)

1. Loading doses:

   • Aspirin 300-325 mg
   • Ticagrelor 180 mg

2. Maintenance therapy (Days 1-21 to 30):

   • Ticagrelor 90 mg twice daily
   • Aspirin 75-100 mg daily

After 21-30 Days

Transition to single antiplatelet therapy 1156:

• Continue ticagrelor 90 mg twice daily alone, OR
• Switch to aspirin 81-325 mg daily

The 2021 AHA/ASA guidelines 6 explicitly state that continuous DAPT beyond 90 days is associated with excess hemorrhage risk.

Critical Caveats

Bleeding Risk Considerations

While ticagrelor is more effective, the 2026 neurovascular stenting study 7 found that ticagrelor was associated with higher rates of any bleeding event (7.27%) compared to clopidogrel (2.33%), though moderate-to-severe bleeding remained similarly low (0.61% vs 0.42%). For patients at very high bleeding risk, this trade-off requires careful consideration.

Alternative for High Bleeding Risk

If bleeding risk is prohibitive, the 2023 guidelines 11 support aspirin monotherapy as an acceptable alternative, though this is clearly less effective in preventing recurrent stroke in poor metabolizers.

Timing is Critical

DAPT must be initiated within 24 hours of symptom onset (ideally within 12 hours) to achieve maximum benefit 158. The Canadian guidelines 5 emphasize that DAPT should be started prior to discharge from the emergency department.

Why Not Standard Clopidogrel-Based DAPT?

The 2018 ACC/AHA guidelines 2 acknowledge that CYP2C19 poor metabolizers have reduced platelet inhibition with clopidogrel, and the FDA issued a boxed warning about this issue. The 2026 meta-analysis 9 confirmed that clopidogrel is 1.29 times less effective in CYP2C19 loss-of-function carriers (p-interaction=0.01), with the interaction effect being even larger (1.63 times) specifically in TIA or minor stroke patients (p-interaction=0.02).

Long-Term Management

After completing the 21-30 day DAPT course, the 2023 guidelines 11 recommend long-term single antiplatelet therapy with aspirin 81-325 mg daily, clopidogrel 75 mg daily, or aspirin plus extended-release dipyridamole. However, for CYP2C19 poor metabolizers, clopidogrel monotherapy should be avoided 49. Ticagrelor monotherapy or aspirin are the preferred long-term options.

Implementation Considerations

The 2026 survey of institutional approaches 10 found that 80% of sites implementing CYP2C19-guided therapy recommend alternative P2Y12 inhibitors for poor metabolizers, with most also doing so for intermediate metabolizers. This reflects growing consensus that genotype-guided therapy improves outcomes without increasing bleeding risk in real-world practice.